COMP <GO>
ABEO vs IMRX // EV/EBITDA & P/E VALUATION
Abeona Therapeutics Inc. (NASDAQ) VS. Immuneering Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: ABEO 1
— IMRX 1
■ METRIC PARITY
LAST: $4.56 (+0.22%) • MKT CAP: $260.8M
valuation
—
LAST: $4.02 (+0.75%) • MKT CAP: $260.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABEO VS. IMRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABEO | IMRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -17.49% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.1 | 43.1 | -7.06 | IMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $260.8M | $260.1M | $675.6K | ABEO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABEO REV | IMRX REV | ABEO GROSS % | IMRX GROSS % | ABEO FCF | IMRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.8M | $0 | 73.7% | — | -$84.3M | -$45.5M |
| FY 2024 | $0 | $0 | — | — | -$58.5M | -$55.1M |
| FY 2023 | $3.5M | $0 | — | — | -$37.0M | -$49.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABEO // BETA —
IMRX // BETA —